.svg)
BLOG
The Latest on Solid IO
Solid IO advances tumor-on-chip platform with clinical feasibility study in breast cancer
Solid IO has initiated a prospective clinical feasibility study in triple-negative breast cancer (TNBC) at HUS Comprehensive Cancer Center, part of Helsinki University Hospital (HUS) in Finland.
Solid IO advances tumor-on-chip platform with clinical feasibility study in breast cancer
Solid IO has initiated a prospective clinical feasibility study in triple-negative breast cancer (TNBC) at HUS Comprehensive Cancer Center, part of Helsinki University Hospital (HUS) in Finland.
Solid IO and Ymmunobio collaborate on cancer drug testing
We're excited to announce a new research collaboration with Ymmunobio, a Swiss oncology biotech company developing first-in-class targeted therapies for solid tumors. Through this collaboration, Ymmunobio will use Solid IO's ex vivo tumor-on-chip platform to evaluate the response of patient-derived tumor tissue to an investigational cancer therapy.
Solid IO joins the Bayer Co.Lab community
The Co.Lab Berlin membership gives us a new way to stay close to the pharmaceutical industry as we develop new approaches for personalized cancer care.
Solid IO welcomes new international investors
Leo Capital and Life Science Invest have joined Solid IO to support the company's next phase of growth in personalized immuno-oncology.
CSO Heidi Haikala receives the Anders Jahre Prize for Young Scientists
The award recognizes her work on understanding why cancer therapies stop working, with the goal of preventing treatment resistance and identifying new therapeutic targets.
Dr. Peter Loskill joins Solid IO as Scientific Advisor
The pioneer in organ-on-chip systems supports Solid IO in bringing human biology into clinical use.
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.